Novartis
Novartis Secures Global Rights to Kyorin’s KRP-M223 for Allergic and Inflammatory Diseases
Novartis, Kyorin Pharmaceutical, KRP-M223, MRGPRX2 antagonist, chronic spontaneous urticaria, Dupixent, licensing agreement
Novartis Acquires Anthos Therapeutics for $925M, Regaining Control of Promising Anticoagulant Abelacimab
Novartis, Anthos Therapeutics, acquisition, abelacimab, anticoagulant, Factor XI inhibitor, atrial fibrillation, stroke prevention, cardiovascular pipeline
Pfizer Appoints Jeffrey Legos as New Chief Oncology Officer
Pfizer, Jeffrey Legos, Novartis, oncology, pharmaceutical industry, leadership change, cancer research
Pfizer Appoints Jeffrey Legos as New Chief Oncology Officer, Bolstering Cancer Drug Development Efforts
Pfizer, Jeffrey Legos, oncology, cancer drug development, pharmaceutical industry, Novartis, leadership appointment
Novartis Reports Strong Financial Performance in 2024, Validating Pure-Play Strategy
Novartis, earnings, pure-play strategy, pharmaceutical industry, financial performance, R&D focus, core therapeutic areas
Novartis Secures Temporary Block on Generic Version of Entresto
Novartis, Entresto, generic version, MSN Pharmaceuticals, temporary block, heart failure drug
Light Horse Therapeutics Secures $62M Series A Funding and Partners with Novartis for Cancer Therapies
Light Horse Therapeutics, Novartis, Series A funding, cancer therapies, small molecule therapeutics, precision genetic editing platform
Light Horse Therapeutics Secures $1 Billion+ Novartis Collaboration on Launch Day
Light Horse Therapeutics, Novartis, biotech, strategic collaboration, small molecule therapeutics, precision genome editing, drug discovery
Novartis Achieves Pivotal Trial Success for Intrathecal Zolgensma in Older SMA Patients After FDA Delay
Novartis, Zolgensma, Intrathecal formulation, Spinal muscular atrophy (SMA), FDA approval, Pivotal phase 3 trial, Older SMA patients
Novartis and BioAge Collaborate on Longevity and Exercise Targets for Age-Related Diseases
Novartis, BioAge Labs, Longevity, Exercise Biology, Age-Related Diseases, Therapeutic Targets, Human Longevity Data, Research Collaboration